drugset / Trial / NCT00618709

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

NCT00618709

Phase 1 Completed 24 enrolled Kythera Biopharmaceuticals
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101

Timeline

Start
2008-01
Primary completion
2008-12
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ATX-101 Peptide 1 unknown Subcutaneous
Subject ATX-101 Peptide 2 unknown Subcutaneous
Subject ATX-101 Peptide 4 unknown Subcutaneous
Subject ATX-101 Peptide 8 unknown Subcutaneous

Indications

No indication recorded.